Pacira to end Exparel co-marketing agreement with DePuy

Eric Oliver -   Print  |

Pacira BioSciences notified DePuy Synthes Sales that its agreement to market and promote Exparel for orthopedic procedures in the U.S. will expire Jan. 2, 2021.

Four things to know:

1. The companies entered into the agreement in January 2017.

2. DePuy's orthopedic representatives collaborated with Pacira's field teams to promote Exparel in orthopedic surgical settings. Pacira's field representatives remained the overall account managers and commercial leads for soft tissue surgeons, anesthesiologists and ambulatory surgery centers.

3. Pacira CEO and chair Dave Stack spoke highly of the partnership but said Pacira developed in-house capabilities to handle promotion in orthopedic surgical settings. Pacira, now, has a large salesforce trained to promote Exparel in these settings.

4. To get out of the agreement, Pacira will pay DePuy an early termination fee.

More articles on devices:
19 spine facilities opening in 2020
153+ ASCs with spine surgery | 2020
DePuy Synthes, AO Foundation extend 60-year orthopedic partnership

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers